Inclusion Criteria:

          1. Histologically proven advanced or metastatic non-small cell lung cancer or squamous
             cell carcinoma head and neck with tumor at least 1 cm in size.

          2. Eligible for treatment with radiation therapy.

          3. Prior treatment: chemotherapy or radiotherapy or surgery.

               1. Prior chemotherapy or radiation must have concluded ≥ 21 days prior to the start
                  of study treatment.

               2. No limit is placed on prior systemic treatment, but subjects must be eligible for
                  immune checkpoint inhibitors therapy, for an FDA approved indication.

               3. No major surgery within 14 days of start of study treatment.

          4. No previous or concurrent malignancy is allowed except for adequately treated basal
             cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which
             the patient has been disease free for the past 3 years.

          5. Age ≥ 18 years.

          6. Life expectancy ≥ 3 months.

          7. Required initial laboratory values:

               1. Absolute neutrophil count ≥ 1,000/mm3

               2. Platelets ≥ 100,000/mm3

               3. Total bilirubin ≤ 1.5 x ULN

               4. AST and ALT if no hepatic metastasis ≤ 2.5 times x ULN

               5. AST and ALT with hepatic metastasis ≤ 5 x ULN

               6. Creatinine ≤ 1.5 x ULN and Requires CrCl ≥ 60ml/min (per 24-hour urine collection
                  or calculated according to the Cockcroft-Gault formula)

          8. Non pregnant and non-nursing women. Women of childbearing potential must have a
             negative serum pregnancy test performed within 7 days prior to the start of treatment.
             Women of childbearing potential and men must agree to use adequate contraception
             (barrier method of birth control) prior to study entry and for the duration of study
             participation. Subjects should use adequate birth control for at least 3 months after
             the last administration of immune checkpoint inhibitors.

          9. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Active clinically serious infection > CTCAE Grade 2.

          2. Serious non-healing wound, ulcer or bone fracture.

          3. Prior treatment with immune checkpoint inhibitors.

          4. Ineligible for immune checkpoint inhibitors based on package insert of the chosen
             immune checkpoint inhibitor (e.g., uncontrolled immunologic disorders, active
             hepatitis, active colitis, active pneumonitis, uncontrolled/active hormone gland
             problems - including thyroid, pituitary, adrenal glands and pancreas).

          5. Major surgical procedure (including craniotomy and open brain biopsy) or significant
             traumatic injury within 14 days prior to registration or those patients who receive a
             non-CNS minor surgical procedures (e.g. core biopsy or fine needle aspiration) within
             3 days prior to registration. There is no waiting period for central line placement.
             There is a 7-day window for recovery prior to registration for patients who underwent
             stereotactic biopsy of the brain.

          6. Participants may not have uncontrolled inter-current illness. This includes, but is
             not limited to: ongoing or active infection; symptomatic congestive heart failure
             (NYHA class III or IV); unstable angina pectoris or new onset angina that began within
             the last 3 months; cardiac ventricular arrhythmias requiring anti-arrhythmic therapy;
             or thrombotic/embolic events such as cerebrovascular accident, including transient
             ischemic attacks within the past 6 months. Uncontrolled hypertension defined as
             systolic blood pressure >150 mmHg or diastolic pressure > 90 mmHg, despite optimal
             medical management. Known human immunodeficiency virus (HIV) infection or chronic
             Hepatitis B or C. Known Grade 3 or 4 neurotoxicity.